A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Signia to Introduce Aspire 3.0 Loyalty Program to Hearing Care Professionals

The reimagined Signia Aspire 3.0 program, launching in early 2022, will include new benefits and professional development opportunities for any practice at any stage of growth

Hearing aid innovator Signia today announced it will preview Signia Aspire 3.0, the most significant update to its industry-leading loyalty benefits program, designed to help hearing care professionals (HCPs) meet their business goals regardless of practice size.

Signia will present Aspire 3.0 to the HCP community at a special online event being held Oct. 26 at 12 PM EDT. All HCPs who attend, whether they are considering joining Aspire or are already a member, can earn 1,000 Aspire points and learn how to customize their Aspire experience to best support their practice. For more information and to register, HCPs can visit here.

Signia will officially launch Aspire 3.0 in early 2022.

HCPs become eligible for Aspire 3.0 by fitting patients with Signia hearing aids, unlocking access to a growing list of baseline benefits, such as consumer marketing funds, Signia-generated patient leads, a dedicated customer service number, free shipping, and more. As an Aspire member enhances human performance for more patients with Signia hearing aids, certain benefits grow with them.

Members of Aspire 3.0 earn points for every qualified order, which they can use in the Aspire store for items like audiological supplies, office equipment, Signia products, and other needs.

“But the new Aspire 3.0 is not merely a points program, nor is it a pricing program,” said Jennifer Wright, Senior Director of Partner Marketing. “It is a partnership program to help HCPs build their practices. We’re delivering these benefits so HCPs can strengthen their clinics, save time, and maximize patient visits.”

Through the newly designed Aspire 3.0 portal, HCPs will have exclusive access to tools that help them stay atop trends and technologies, a dashboard for tracking leads, easy access to their benefits, and opportunities to unlock an even richer Aspire 3.0 experience.

“We created Aspire 3.0 to be the exact opposite of one-size-fits-all,” Wright continued. “This new program was developed to deliver benefits that can help any practice, small or large. And as a practice grows, so can its access to Aspire programs and features, allowing HCPs to continually differentiate themselves, stand apart from their competition, and grow professionally within the communities they serve.”

Beyond the baseline benefits, Aspire members can qualify for and choose from various available Bonus Benefits, such as extra co-op dollars, points, or rebates, depending on their type of membership. Plus, Aspire members can take advantage of services to support their business, such as supplemental insurance for themselves and their employees, financing discounts, financial investment options, access to online business services, and more.

“As practices grow, they can have a deeper, more beneficial relationship with the Aspire program and our partners,” Wright concluded. “Through available bonus benefits, HCPs can really go higher with Aspire.”

For more information on Signia Aspire 3.0 or to become a member, click here or contact your local Signia team.

 

SourceSignia
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy